Home / Transcripts / OptimizeRx Corporation (OPRX) · March 5, 2026

OptimizeRx Corporation (OPRX) Earnings Call Transcript

March 5, 2026

NASDAQ US Health Care Health Care Technology earnings 46 min

Earnings Call Speaker Segments

Steve Silvestro executive
#1

Thanks, operator. Hello, everyone, and welcome to the call covering our fourth quarter and fiscal year 2025 results this afternoon. We turned in a robust fourth quarter that came in above consensus estimates as well as our own internal expectations. Q4 revenue came to $32.2 million, while adjusted EBITDA reached $12 million. On a full-year basis, revenue came in at $109.4 million, and adjusted EBITDA was $24.3 million. The results we posted for full year 2025 make plain how strong our operating model is and how large the opportunity in our market remains. We put up solid top-line performance both among our biggest, most established clients and among a growing group of newer customers, especially mid-tier and long-tail life science companies. We see that segment as very attractive, offering a substantial runway for growing our customer base and deepening relationships as time goes on. Meanwhile, a better product mix and our channel partner strategy helped push gross margins higher in 2025. Combined with cost optimization work done after the Medicx acquisition and the advantages of an operating model that is largely fixed cost and highly scalable, we more than doubled adjusted EBITDA and free cash flow compared with the prior year. Although we're happy with how the fourth quarter went, year-to-date contracted revenue figures are showing softness relative to last year. The main cause is a market shift away from managed services that we previously communicated, which had made up a material share of contracted revenue during the first half of 2025. On top of that, we think certain clients are taking a more cautious spending posture in the early part of 2026 as they rework their portfolios in response to Most-Favored-Nation pricing. We're confident the latter is a temporary situation that should begin returning to normal over the next few months. Against that background, we're revising our 2026 guidance and adopting a more conservative revenue view while keeping our focus on profitability. For 2026, we anticipate revenue between $109 million and $114 million, and adjusted EBITDA between $21 million and $25 million. Let me also be clear about something. Management and our board see meaningful opportunity for value creation still ahead, especially when we look at the demand and operating leverage evident in 2025. Fiscal 2025 showed how well our profitable growth model works; we hit Rule of 40 performance, posted adjusted EBITDA margins above 20% for the year, and produced nearly $19 million in free cash flow from operations. As a sign of our confidence in the business's long-term value, our board has approved a $10 million share repurchase program. We plan to fund that repurchase with available cash and cash equivalents through open market or privately negotiated transactions. I'd also like to speak to some of the speculation and questions we've gotten about artificial intelligence. AI has caused minimal disruption to our business. We don't anticipate any disruption from it going forward. We're not just another commoditized software offering—we function as a strategic ally for life sciences organizations, powered by a proprietary communications network of significant value that links drugmakers to healthcare providers and patients during pivotal care moments. In fact, AI could actually act as a favorable force. Customers have told us that in the past, as much as 50% of marketing budgets went toward producing content. As AI creates efficiencies across our client base, those funds are probably going to be redirected toward broadening reach and sharpening how marketing gets done—precisely the areas where OptimizeRx holds a strong advantage. We think our position sets us up well for superior long-term results on revenue and earnings alike. We tackle major challenges for those we serve, such as boosting brand awareness, cutting down on prescription abandonment, making disparate point-of-care platforms work together more smoothly, and aiding the shift toward specialty and more complex medications. A powerful illustration of what we can do involves one of our biggest clients, a top 10 pharma maker that brought in OptimizeRx for particular oncology efforts using our point-of-care and point-of-prescribe-based marketing offerings. Though the earliest initiatives centered on narrowly defined use cases, outcomes showed real, measurable success in connecting with prescribers inside a clinical workflow and shaping involvement at crucial decision moments. Once performance confirmed the DAAP model worked, this manufacturer boosted its commitment to OptimizeRx during 2025 to back numerous oncology brands spanning a range of indications. That broadening across brands and tumor types generated significant year-over-year revenue gains, growing from preliminary pilots into a large-scale, multi-brand oncology strategy. This is exactly the kind of momentum we aim for when discussing enterprise engagements. We're likewise experiencing considerable traction within med tech. A leading client initially came aboard after COVID to widen prescriber access through our older point-of-care marketing tools. Steady script growth throughout 2024 led this client to embrace DAAP—our AI-driven dynamic audience activation platform—which enabled accurate, well-timed outreach to prescribers, among them plenty of fresh prescribers never reached before, precisely at the most critical point in the patient journey; this remains a key point of distinction for us and for those we serve. By engaging and capitalizing on these valuable HCP audiences pinpointed via DAP, the client quickly broadened rollout to more brands and channels; this expansion across multiple brands and channels is generating major results in a fiercely competitive and fast-expanding space. Because the program succeeded, this customer sharply raised its spending on OptimizeRx offerings, going from pilot-level amounts in 2022 to several million dollars by 2025. This sequence—beginning with focused POC engagement, moving into DAP adoption, then speeding up across the portfolio—demonstrates the repeatable route to faster growth and better ROI that we observe among dozens of comparable pharma and med tech firms. OptimizeRx holds a distinctive position to fuel lasting long-term growth and shareholder value. The crucial term here is sustainable. Having built one of the country's biggest point-of-care networks—and the sole genuinely point-of-prescribe one—we let drugmakers reach clinicians directly at the very moments that count most, when real choices are under review and getting finalized. On top of that base, we created an omnichannel platform built for this specific purpose, one that brings in sophisticated patient-finding tools like DAAP and Micro-Neighborhood Targeting; through these, the way pharma firms, doctors, and patients link up is being redefined, which lifts patient outcomes and reshapes engagement throughout the healthcare ecosystem. Because we span both point-of-care and direct-to-consumer channels, we hold a lasting competitive edge. In our view, OptimizeRx stands alone in possessing the scale, technology, and data integration needed to connect providers and patients smoothly across every channel; that makes us a full-service commercialization partner, helping clients over the entire product life cycle, strengthening ties, and growing long-term value capture. As we've said on earlier calls, a main priority going forward is showing even more clearly our reach, scalability, and worth as a dependable strategic partner. The fact that we keep growing ties with our biggest clients highlights the value we bring and the effect we have on script lift during commercialization. I have no doubt that staying focused on execution—even with certain near-term headwinds in our sector—alongside our distinctive platform and robust customer results, will turn into significant long-term shareholder value; we think our momentum puts us in position to grab more market share and broaden our part in pharma's multi-billion dollar digital ecosystem. Our clients stay deeply woven into our HCP and DTC offerings, and we aim to serve them without friction across the whole patient care journey. With that, I want to hand the call over to our CFSO, Ed Stelmakh, who'll take us through the financials. Ed?

Edward Stelmakh executive
#2

Thank you, Steve, and good afternoon to all of you. We put out a press release covering the financial results for our fourth quarter and fiscal year that closed on December 31st, 2025. You can view a copy and download it from the investor relations portion of our website. You can also find further details in our upcoming Form 10-K. Revenue for the fourth quarter reached $32.2 million. That figure was mostly consistent with what we had previously told you to expect, since we kept shifting a greater share of our DAAP agreements over to subscription revenue that is distributed more evenly across the year. On top of that, buy-ups arrived at a more modest level than they did in 2024. Gross margin rose to 74.8% for the quarter ending December 31st, 2025, up from 68.1% for the quarter ending December 31st, 2024. This year-over-year gross margin growth reflects a favorable mix of solutions and channel partners. Although the fourth quarter delivered a record gross margin, we do not expect gross margins to remain at that level in 2026, and we still think we will land in the mid 60% range, because the fourth quarter included an unusually large amount of specialty messaging in higher margin channels, which was a beneficial but atypical mix for us. Our operating expenses for the quarter ending December 31st, 2025 fell by $2.9 million compared with the prior year, mainly because of lower cash OpEx stemming from the post-acquisition cost reduction measures we put in place in 2024. At the same time, net income reached $5 million, or $0.26 on a fully diluted basis, for the fourth quarter of 2025, versus a net loss of $0.1 million in the fourth quarter of 2024. On a Non-GAAP basis, net income for the fourth quarter of 2025 totaled $9.9 million, or $0.51 per diluted share outstanding, compared with Non-GAAP net income of $5.5 million, or $0.30 per diluted share outstanding, in the same period a year ago. Adjusted EBITDA reached $12 million for the fourth quarter of 2025, up from $8.8 million in the fourth quarter of 2024. We closed out the year with cash and short-term investments of $23.4 million as of December 31st, 2025, compared with $13.4 million as of December 31st, 2024. Even though we paid off $8 million of principal during 2025, including $6 million ahead of our prepayment schedule, we still managed to grow our cash balance over the course of the year. Operating cash flow was $18.7 million for 2025, versus $4.9 million in 2024. Consequently, our debt balance currently sits at $26.3 million. We remain confident that we are well-funded to pursue our strategic and operational objectives, and we intend to use free cash flow to reduce debt at an accelerated pace while also looking for opportunities to repurchase shares. Now I'd like to discuss our KPIs for the 12 months ended December 31st, 2025. Average revenue per top 20 pharmaceutical manufacturer was $2.8 million, a slight decline from $3 million in 2024, which was directly attributable to the lower buy-ups and data-related revenue I mentioned earlier. At the same time, our net revenue retention rate is still solid, sitting at 116%, while revenue per FTE reached $839,000, which is above the $701,000 figure we reported for the 12 months that ended December 31, 2024. Last, I want to give some extra detail on our guidance, which now anticipates 2026 revenue landing somewhere between $109 million-$114 million, with adjusted EBITDA in the range of $21 million-$25 million. As you might remember, managed service revenues gave a boost to our first half 2025 revenue, adding roughly $9 million during the first half of 2025. Because we aren't expecting a comparable revenue mix in 2026, the phasing of our revenue will probably follow the historical 40%-60% split between the first and second halves of the year. With that, I'll hand the call back to Steve. Steve?

Steve Silvestro executive
#3

Thanks, Ed. Operator, now let's move to Q&A.

Ryan Daniels analyst
#4

Hey everyone, appreciate you giving us the chance to address some questions. I'm interested in what you shared regarding certain softness in end markets — I've got a couple of things to ask. First, is this really just cautious behavior coming from those 17 companies involved in MFN negotiations, or is it something wider that touches your whole client base? That's my first one.

Steve Silvestro executive
#5

Okay, Ryan — appreciate the question, and it's nice to hear from you. What we're observing is a wider slowdown taking hold among every one of our clients, since they're still working out what this will actually mean on their end. On the length of contracts, we've seen some shortening — from roughly six months to twelve months, now down to quarter-by-quarter or even half-year increments, while they weigh how to allocate their budgets. My sense is this will settle down eventually, and we believe it will settle down as they work through it. Setting aside those folks, I'd say it mostly comes down to excessive caution during the first quarter; that's our read, and it matches what we're picking up. Basically, people are simply being careful.

Ryan Daniels analyst
#6

All right. When it comes to DTC and HCP marketing, are you noticing any distinctions, or is pressure coming from your partners on both fronts?

Steve Silvestro executive
#7

Yeah, it's pretty consistent everywhere. At this stage, none of the manufacturers see them any differently. Everyone holds an identical perspective on both DTC and HCP, and on spend overall.

Ryan Daniels analyst
#8

Alright. Alright, that's useful. So perhaps one for Ed. You said gross margins during the quarter were clearly strong and generated a lot of upside on the bottom line. I believe you mentioned there was some specialty messaging and channels with higher margins. Could you elaborate a bit more on what that consisted of or what caused it, and then why you feel that can't continue? Is it simply something you'd rather not model, but in a particular quarter you might pull it off again and push margins up through those specialty messages?

Edward Stelmakh executive
#9

Hi Ryan, and thanks for asking. So, there are really a couple of pieces to this. To start, let's talk about what took place during the fourth quarter of 2025. During that period, we benefited from an extremely strong and advantageous blend of channel partners, which we leveraged to get our messaging out. As you're aware, we have the ability to select which channel partners receive which messages, and obviously we will push those messages via partners that let us connect with the strongest audience under DAAP. That explains how we managed to achieve better margins in that quarter. Now, when it comes to 2026, our guidance points to a gross margin range in the mid-60% area. The primary reason is that we aren't at ease assuming the upper end of that range and sustaining it across the full year. We're capable of doing so from time to time, yet I don't anticipate us operating that way consistently all year long.

Ryan Daniels analyst
#10

All right, thank you. Perhaps for the final question, I'll return to Steve. You said you aren't observing any disruption coming from AI, and I'd really like to hear your perspective regarding how it is in fact assisting your operations. I'm aware that previously you've applied AI in certain areas like real-time analytics and product deployment. I'm just wondering what AI has represented for you, perhaps across the past 2 quarters, and what you're putting money into as we look ahead over the coming several years to improve your offering or your ROI for clients. Thanks.

Steve Silvestro executive
#11

Sure thing, Ryan. Glad to discuss that. What Ed brought up is really where this builds from — namely, the excitement everyone has around Agentic AI being rolled out everywhere. As you're aware, this is something we've done for a number of years, so for OptimizeRx it isn't a fresh thing. The result is that organizations gain speed and efficiency. To actually make progress, human involvement remains necessary. The opportunity this gives us is helping customers quit pouring funds into areas such as content creation or similar activities that were heavily staffed, and instead begin using AI so they can direct more dollars toward commercial execution — and that's an area where our strengths really stand out. The AI component is something we're enthusiastic about; we don't view it as a threat to us whatsoever; we view ourselves as helping people embrace more AI; and building on what Ed said regarding selecting channel partners and deploying messages that affect the profile, I believe that's a perfect illustration of how AI might benefit OptimizeRx as greater numbers of people take up Agentic and other pieces of AI now emerging. It lets us operate with greater efficiency in channel partner distribution, message distribution, and physician identification. We embrace it. In my view it isn't mature enough at this point, Ryan, for us to be ready to change the business's profile when it comes to margins, yet we could publicly signal that and demonstrate the potential inside this business as we keep expanding it. For me personally, this is quite exciting. I'm working to avoid overselling it, but for us it's a positive, a net positive. Thanks for bringing it up.

Ryan Daniels analyst
#12

Okay. Thanks for all the color, guys. Appreciate it.

Steve Silvestro executive
#13

You got it. Thanks for the good questions.

Edward Stelmakh executive
#14

Yeah, thanks, Ryan.

Eric Martinuzzi analyst
#15

Yeah. In the past, you've provided some insight into what portion of revenue is contracted. Based on the duration details you shared, Steve, my guess is that figure isn't at the level you'd previously described — the 30% mark you mentioned before. Could you offer any insight into the percentage under contract?

Steve Silvestro executive
#16

Yeah, we can share a bit of insight. I mean, at present we're approximately... If we exclude the managed service piece, Eric, that we discussed, which is mostly contracted in the first half, we're about 15%-20% below our usual level. That's largely because of contract timing and contract duration. Once you remove the managed service piece, it's mainly about how long contracts last, meaning shorter-term agreements than what we'd have seen at this point last year or in earlier years. We're not panicking about that, in our view. We believe that will correct over time, and we believe that by mid-year, you know, we'll begin to see the contracted revenue figures resolve on their own and, you know, return to normal. Ed, please jump in if you'd like. I'm aware that you and Andy are monitoring this very closely as well.

Edward Stelmakh executive
#17

I believe your take is on point, Steve. So, somewhere in the range of 15%-20% below what we saw a year ago. Normally we won't reveal the precise share of revenue that's already contracted, though we do provide a sense of whether we're tracking ahead or trailing. To add a bit more detail, like Steve mentioned, managed services had a fairly significant material effect during last year's first half at roughly this same point. Largely absent from this year's picture is that piece. On top of that, shorter duration contracts are also affecting us somewhat right out of the gate. We're sort of taking the market's temperature, and we feel quite positive and quite optimistic about pharma once they make it past the first quarter or two of this year, get their spending normalized during the year, and return strongly in the back half of the year.

Eric Martinuzzi analyst
#18

To expand on what was mentioned regarding managed services, I believe you noted something was there. Did that $9 million figure apply to the first half, or did it represent $9 million for 2025 overall?

Edward Stelmakh executive
#19

During the first half of 2025, revenue came to $9 million.

Eric Martinuzzi analyst
#20

Regarding the 2026 guidance, is there any portion in there for managed services?

Edward Stelmakh executive
#21

Only a minimal amount. Like we mentioned during the prior year, managed services represents a highly irregular offering on our part. It appears and then disappears. We aren't anticipating a great deal of that arriving in 2026.

Eric Martinuzzi analyst
#22

Understood. I appreciate you answering my questions.

Edward Stelmakh executive
#23

Sure thing.

Steve Silvestro executive
#24

You got it, Eric. Good questions. Thanks.

Constantine Davides analyst
#25

Thanks. Steve, during your prepared comments, you mentioned how mid-tier and smaller manufacturers have been performing. I'd like to know precisely what steps you're taking to go after that segment of the market, and what has fueled that achievement?

Steve Silvestro executive
#26

Hi, Constantine. The truth is, we're capable of filling in much of what those mid-tier and long-tail customers lack when it comes to infrastructure inside their own operations. Consider how OptimizeRx is becoming a commercialization ally for many of these assets, as these businesses bring new products to market, introduce them, and work to generate revenue. Where they might lack substantial funds for sizable marketing departments, luxury-level funding for agencies, or hundreds of sales representatives in the field, we can occupy much of that vacant area. We bridge that divide extremely smoothly, in a manner that's economical and, well, productive. Expansion among the mid-tier and the long tail has gone beyond what we anticipated; the increase there is happening more quickly than we originally expected, and that's an extremely encouraging indicator. Turning back to something Ryan asked about, regarding those parties negotiating on the MFN side, every one of them ranks among the top, well, the top 10 manufacturers, correct? These are the Lillys, the Pfizers, and all the others whose names are recognizable to everyone. Specialty pharmaceutical volume continues to originate from the mid-tier, the long tail, and the biotech segment; that's an especially compelling prospect for our company, so we're focusing our attention there. Thank you. That's an excellent question.

Constantine Davides analyst
#27

Great. Regarding where you're putting your capital, I noticed that a share repurchase plan was announced by you folks, and I'm just attempting to consider, you know, how or to grasp the way you're approaching reducing debt against directing it toward buybacks. Just, you know, what ought we to anticipate in that area.

Steve Silvestro executive
#28

Sure. Ed, that one is yours to address.

Edward Stelmakh executive
#29

Okay, thank you, Steve. Hello there, Constantine. Yes, indeed. Each chance that presents itself will get our full consideration. You're aware that our practice in the past has been to reduce borrowings using every dollar of surplus cash generated. Our intention is to keep doing so to the greatest extent we can during this year too. Beyond that, we'll weigh it against the chance to step in and repurchase shares of our company when the valuation makes sense. The simple response to what you're asking, I suppose, would be that it all depends. Generally speaking, I believe you should anticipate that we'll direct those funds toward lowering what we owe.

Constantine Davides analyst
#30

Understood; so perhaps just one more for you, Ed. Regarding the guidance, what have you taken into account for the approximate NRR this year?

Edward Stelmakh executive
#31

When it comes to NRR, as I mentioned, we consistently aim for anything beyond 100% as a solid benchmark; we haven't actually broken down our guidance around particular NRR figures, though I believe if you consider our current guidance, there's likely a bit of space for a modest amount over 100%.

Constantine Davides analyst
#32

Got it. Thank you.

Steve Silvestro executive
#33

Thanks, Constantine.

Jeff Garro analyst
#34

Okay, good afternoon, and I appreciate you taking my questions. So, I was hoping to get a few additional follow-ups regarding the dynamics in the end market. I'll throw out a couple to kick things off, really centered on how customers are behaving, and I'm curious whether you can share any observations about what bookings in January and February looked like compared with December, when those big pharma companies were still in the process of working out those Most-Favored-Nation pricing agreements. And then, when we consider the lower spending early on here in 2026, does that probably mean there will be more catch-up spending during the back half of the year? Or could it be that, you know, that portion of the budget simply won't be recovered this year? Is there any specific feedback or anecdotes you're picking up from your customers that would back up what the likely behavior in the back half will be?

Steve Silvestro executive
#35

Hey Jeff, great to hear from you. Regarding the dynamics we're currently observing in the marketplace — which are pretty much in line with what everyone across our peer group, that you're either tracking or familiar with, is seeing — it's precisely what we mentioned, correct? Everybody is somewhat distracted by the MFN negotiations. Even if they aren't directly involved in those talks, they're kind of waiting to see how things play out; we do believe that creates disruption during the first, you know, first half of the year. That's the reason we've tweaked the guidance to account for it. We do believe the business will return to its traditional 40/60 split when it comes to revenue flow; that would indicate the back half is likely to be somewhat stronger than the first half. As for, you know, how January, February, and so on are shaping up, we've already provided a contracted revenue figure and informed you that we did $9 million in the first half; so you'd need to, you'd need to exclude that since we know it won't be repeated; we told you basically where things stood year to date. That ought to give you the, you know, the information you're after. You know, we're feeling quite confident about how we'll reach the first half, and we feel even more confident about the back half. The discussions we're having right now with clients, the client satisfaction that our chief commercial officer is reporting back to us, has us feeling bullish about the back half of the year. Again, we've lowered the guidance a bit on the top line simply to adjust for some of the items we've already discussed. We've reaffirmed and increased the guidance on EBITDA, so that should be, I think, a fairly good indicator of how we view the year. Glad to take more questions about the dynamics, but I think that probably covers what you're asking about.

Jeff Garro analyst
#36

Okay, that's all really useful. Maybe I can dig a bit deeper on visibility and the changes in the business that are meant to produce steadier results. Could you give us an update on the effort to turn some of your DAAP agreements into subscriptions? At one point in 2025, I believe that represented more than 5% of yearly revenue — that's my assumption for 2025. In a more recent update, you mentioned having a line of sight toward raising that to 10%. It would help to hear whatever detail you can offer about where that subscription mix stood as 2025 came to a close, and how you expect it to develop in 2026.

Steve Silvestro executive
#37

Absolutely. Andy, could you speak to the conversion factor specifically, please? Jeff, I’m not sure whether we’ll reveal a figure at this point — Andy can walk you through the trend we’re observing, and what I’d say is that we feel quite positive about it. Andy, would you go ahead and address that?

Andy D'Silva analyst
#38

Sure, we nearly hit 10% when it comes to that run rate as we closed out the year. Clearly, that wasn't the case across the whole year. For the full year, we landed somewhere in the 5% to 10% range. When you look ahead to 2026 and beyond, if DAAP keeps growing as a share of our total business, my expectation is that you'd begin to see the subscription portion of the business keep rising, and DAAP stands as a central priority for our growth.

Jeff Garro analyst
#39

excellent, and I appreciate your fielding our questions.

Steve Silvestro executive
#40

thank you, Jeff, and thank you as well, Andy.

David Grossman analyst
#41

Hey everyone, good afternoon. Appreciate you letting me ask something. I just want to sort of establish a baseline regarding the macro assumptions that sit behind the updated outlook for 26. So, is your view that things have more or less settled at one level and ought to hold steady or rise from where they are now? Or are you factoring in further deterioration? Perhaps you could share a bit more detail on what your thinking looks like there, and how that got reflected in the guidance, the updated guidance.

Steve Silvestro executive
#42

Sure. Ed, do you wanna take that one?

Edward Stelmakh executive
#43

Yeah, I'm able to address that. Yeah. Yeah. What I'd say is that, yeah, the beginning of this year has definitely been slower than what we'd been hoping to see. The way we're looking at it right now is that as we move through the year, improvement should begin to show up in these areas. Our hope is that Q2 and Q3 are when that really starts to materialize. That's what the markets are telling us — they've been pausing somewhat, working to absorb what MFN is going to mean for their own portfolios. Right away, they're committing to contracts with shorter durations, though in time they'll start spending again and keep marketing the way this industry has done for a great many years.

David Grossman analyst
#44

Would you say we're looking at a heavier fourth quarter, with the year weighted toward the back half, compared to what we normally see in Q4 — or do you think it'll be about the same?

Edward Stelmakh executive
#45

Making a forecast is difficult, though it is sort of. My perspective on this resembles what we saw several years back, when FDA approvals slowed down. The pharmaceutical industry keeps a very close eye on things like that. Whenever any sort of interruption or shift in direction occurs, they tend to press pause or ease off the gas somewhat, then return with strength during the second half of the year.

David Grossman analyst
#46

Understood; regarding net revenue retention, what portion of the fourth-quarter drop stems from managed services, or did managed services in the fourth quarter look comparable, you know, to what you observed in the fourth quarter a year ago? I'm just trying to understand, since it appears NRR slipped somewhat in the fourth quarter, and I'm simply asking whether that's genuinely connected to what's happening with managed services or whether other factors are involved there, such as the lower spending.

Edward Stelmakh executive
#47

Yes, that's part of it. Another part involves the quarters — the buy-ups, plus the shift to a subscription model that took place in 2025. That simply evened out how revenues get recognized. Both of those things play a role in the decline.

David Grossman analyst
#48

Understood. So Steve, regarding what you said about AI, when you engage with these major pharma organizations, what do they tell you about their in-house initiatives and the areas where they're looking for you to step in?

Steve Silvestro executive
#49

Yeah.

David Grossman analyst
#50

What's their approach, you know, when it comes to putting AI to work over on the marketing side of things?

Steve Silvestro executive
#51

Absolutely, I'm glad to talk about that. I understand we're planning to see you next week, so we'll have a chance to discuss it further then. What they're primarily focused on at the moment is examining this for, essentially, their internal operations — specifically how they organize clinical trials, with the goal of making that process more efficient. Large language models are a big part of that, and they want to train on them. They're also aiming to take advantage of data collected from companies such as IQVIA or Surescripts, or whichever other suppliers they've gathered information from over the years, and begin putting some of that to use in what I'd call a more direct manner, generating efficiencies in the process. Those are the main objectives they have in mind. I've already mentioned the content creation comment data, and that one is massive. As everyone participating in this call is aware, the volume of content that pharma produces is tremendous. Should they be able to harness some of these emerging tools to essentially remove the manual effort involved in producing all that content — along with the approval workflow that prevents that content from being rolled out promptly — that would represent an incredible breakthrough for the industry. The single greatest source of frustration for pharmaceutical marketers is navigating the medical, legal, and regulatory review. One thing they're seriously exploring is harnessing AI to remove the requirement of going through that whole process in the form it takes today. Consider medical simulations, for instance. Consider legal, for instance. Clearly, legal represents an enormous area that this could upend, correct? When it comes to regulatory matters, it's the same story. All of those are domains where large language models and AI are more than capable of disrupting or substituting for what currently happens there. If pharma manages to successfully implement what McKinsey and other firms are actually calling Agentic AI, they'll be able to accelerate how quickly they bring things to market. Drugs — getting them through approval, getting them launched, getting them deployed, all of that — will happen rapidly; it will be considerably quicker than is the case today. That would leave them with far greater marketing opportunity and a larger marketing budget to devote to execution, which is precisely where they want their money going; that's where we come in. Our position is on the execution side, not on the— Right.

David Grossman analyst
#52

Yeah, it is. Thank you very much.

Steve Silvestro executive
#53

Yeah, absolutely.

Constantine Davides analyst
#54

I appreciate you giving me the chance to ask one more. Steve, toward the close of 2026, your company revealed some fresh alliances and moved a few of them into exclusive setups. I'm curious whether you could discuss what you're continuing to do in that area. My sense is that, you know, with one exception, that space had already been thoroughly covered, but how much additional runway remains in both the EHR space and the standalone, ePrescribe space?

Steve Silvestro executive
#55

Yeah. I appreciate that, Constantine; that's an excellent question; it matters that the group understands, that everyone understands, EHR and ePrescribe aren't the same thing at all, and each EHR contains an ePrescribe module built into it; sometimes the ePrescribe is owned by the EHR itself and is native; other times, an ePrescribe has been integrated into it; those represent two distinct connectivity points on our end. Our real emphasis is on growing not only our EHR footprint, but also what we refer to as our point-of-prescribe footprint. The rationale there is that we want to be certain we're participating actively in the digital conversation with the prescriber at the moment they're considering the diagnosis and prescription therapy selection and then sending that prescription along to whichever pharmacy it will reach following the Real-Time Benefit Check and all the rest of it. It has less to do with platforms we lack. It has more to do with deeper integrations into those platforms and ensuring we stay consistently embedded in every portion of the workflow where we possibly can be; regarding your exclusivity question, we did sign, we managed to pull away some channel partners from rivals who had entered into agreements with those particular channel partners and either neglected to pay the channel partner, neglected to perform, didn't come through on what they promised they would come through on. Those channel partners came directly to OptimizeRx via our channel lead, who has done an outstanding job cultivating these relationships and wanted to join the network. From my perspective, that's a tremendous positive signal that we treat our partners well and work hard to be the strongest partner we can be for them, and that explains why more people keep arriving. I look forward to sharing more details about that. I won't reveal names on this call, Constantine, but eventually, you'll see press releases containing the names and joint statements from me and those additional channel partners arriving in the not-too-distant future.

Constantine Davides analyst
#56

I appreciate the extra detail.

Steve Silvestro executive
#57

Did that... Yeah, you have it. Was that an answer to what you asked? I just want to confirm I understood.

Constantine Davides analyst
#58

Absolutely. Yeah.

Steve Silvestro executive
#59

Okay. Thanks, man.

Steve Silvestro executive
#60

Thank you, operator. And thanks to everyone for being with us today. I want to wrap up by offering my congratulations and gratitude to the whole OptimizeRx team for an outstanding 2025. We are truly grateful for their commitment and effort as we work through a digital pharma marketing environment that keeps getting more complicated and moving faster all the time. Big changes are underway in our industry. When it comes to how pharma brands, patients, and prescribers link up, our offerings stand in a distinctive spot to reshape that connection. Innovation and execution keep getting powered by our mission-driven culture, which lets us bring in and keep solid partnerships while strengthening our standing as a dependable, long-term technology ally. This industry is still fairly young, and we're only at the beginning of what's possible — yet we have no doubt that our demonstrated business model, our solutions, and our tech platform speak directly to what our customers need as those needs shift. With real-time brand eligibility signals driving our synchronized HCP and DTC marketing capabilities, plus added functionality like Micro-Neighborhood Targeting, we can reach hyper-local, privacy-safe audiences among both patients and prescribers. Our competitive moat keeps widening thanks to these distinctive capabilities, and our market leadership keeps getting stronger. Looking at the rest of the year, we know exactly what we're prioritizing. Two things have our sharpest attention: getting customers to use DAAP more intensively, and making revenue more predictable by moving a greater number of customers onto a subscription-based model. A steady recurring revenue component matters enormously as we push toward becoming a sustained Rule of 40 company; in our view, these efforts will be transformative and lie at the heart of creating long-term shareholder value for OptimizeRx. Once more, thank you for your time today. I can't wait to talk with you on our next earnings call and to meet up with many of you at the industry conferences coming up. Operator, please go ahead with OptimizeRx's Safe Harbor Statement.

Operator operator
#61

Thanks very much, sir. As we wrap up today's call, I'd like to read the company's safe harbor statement, which contains key cautions about forward-looking statements delivered on this call. Anything management has said today could include forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, along with Section 21E of the Securities Act of 1934, as amended; you shouldn't rely on such forward-looking statements when making investment decisions. Terms such as anticipate, estimate, expect, possible, and seeking, plus comparable expressions, signal forward-looking statements. Such statements speak only as of the date they were made. During this call, we'll make forward-looking statements. Those statements address our intention to generate sustainable growth over the long term, our strategy for building shareholder value, bringing more clients onto our recurring revenue model, achieving and maintaining Rule of 40 status, the durability of how we operate, the expectation that AI will cause only limited disruption, opening up fresh chances to grow revenue profitably, making our revenue sources more forecastable, delivering significant operating leverage, projected 2026 figures for revenue and adjusted EBITDA, superior long-term results on both the top and bottom lines, ongoing strong momentum within medtech, the capacity to enhance patient outcomes and reshape engagement throughout the healthcare ecosystem, our ability to steadily deepen ties with our biggest accounts, our estimate of the total addressable market, the chance to gain further market share and broaden our position in the pharma digital ecosystem, market penetration, revenue growth margin, operating expenses, profitability, cash flow, technology, investments, growth opportunities, acquisitions, and announcements we plan to make soon. Management's outlook for the remainder of the year falls within what we call forward-looking statements. We take on no duty to update or revise any such statements publicly, whether because of fresh information, later occurrences, or any other reason. By their very nature, forward-looking statements carry risks and uncertainties, and certain of those can't be foreseen or measured. What actually happens and what we ultimately report may diverge substantially from what these statements describe, envision, or imply. Forward-looking statements come with a range of risks and uncertainties. These include things like the impact of government regulation, competitive pressures, reliance on a small set of customers, cybersecurity events that might interrupt operations, staying current with technology that keeps growing and changing, keeping contracts in place with electronic prescription platforms and electronic health records networks, plus other significant risks. Details about the risks and uncertainties that forward-looking statements face and that could impact business and financial results appear in the company's annual report on Form 10-K covering the year that ended December 31st, 2023, along with other documents the company has filed and might file with the SEC down the road. Once those documents get filed, you'll be able to find them both on the company's site and through the SEC's site, sec.gov. As we wrap up this call, a quick note: a replay of the audio from today's conference will be posted this evening, and it will stay up for twelve months in the investor area of the company's website. We appreciate everyone taking the time to be here today. That's all we have for this conference call. Feel free to hang up whenever you're ready.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OptimizeRx Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to OptimizeRx Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.